Therapeutic Confirmatory (Phase III)

3,259 trials 1,319 recruiting

Filter these 3,259 trials by condition, country, sponsor and more.

Open in Search →

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 2019-05-24
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS) Ended

2023-503898-38-00 Atopic Dermatitis 2019-05-24
Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su… Ended

2022-501971-24-00 Adjuvant treatment of HCC 2019-05-20
A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended

2023-509304-16-00 Pulmonary arterial hypertension (PAH) 2019-05-16
EASE SBS 2 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome) (SBS) Ended

2024-513374-22-00 Short Bowel Syndrome 2019-04-30
Dexamethasone in Herpes Simplex Virus Encephalitis Open label Randomized Controlled Trial with an Observer-blinded evaluation at 6 months Ended

2024-515985-16-00 Herpes Simplex Virus Encephalitis 2019-04-25
Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality Ended

2022-502187-20-00 Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3 2019-04-11
HELIOS-A: A Phase 3 Global Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis Ended

2023-508365-33-00 Hereditary Transthyretin Amyloidosis 2019-04-09
A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended

2023-505476-29-00 Giant Cell Arteritis 2019-04-05
Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome. Ended

2024-515247-28-00 Hypereosinophilic Syndrome 2019-03-29
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 Ended

2024-510751-34-00 Gaucher's disease type I; Gaucher's disease type III 2019-03-26
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended

2022-500395-57-00 Resectable high-risk Locally Advanced Cutaneous Squamou 2019-03-04
This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa… Ended

2022-502747-35-00 Newly diagnosed advanced (FIGO stage III-IV) high grade 2019-02-18
A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patien… Ended

2023-508424-34-00 Moderate to Severe Plaque Type Psoriasis 2019-02-11
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Su… Ended

2023-506687-13-00 Primary Generalized Tonic-Clonic Seizures 2019-01-31
Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) Administered by Intravenous Infusion Every 4 Weeks in Patients With Fabry… Ended

2024-516735-27-00 Fabry disease (α-galactosidase A deficiency) 2019-01-31
Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended

2023-508343-48-00 Adult patients with relapsed or refractory aggressive B 2019-01-25
Study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated l… Ended

2024-511490-29-00 Non-small cell lung cancer 2019-01-24
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended

2022-502936-38-00 Moderate and Severe Atopic Dermatitis 2019-01-09
A Study of the Efficacy and Safety of Golimumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-507142-83-00 Ulcerative Colitis 2019-01-09
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin… Ended

2024-513513-12-00 Cholangiocarcinoma 2019-01-06
First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended

2022-502124-52-00 Advanced epithelial ovarian cancer 2018-12-18
A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in… Ended

2024-512158-12-00 Bladder Cancer Muscle-Invasive Bladder Cancer 2018-12-14
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended

2022-502938-30-00 Moderate and Severe Atopic Dermatitis 2018-12-10